O4 - Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). - Powles, T.; Motzer, R.J.; Escudier, B.; Heng, D.Y.C.; Scheffold, C.; Clary, D.O.; Choueiri, T.K. (European Urology Supplements, 2016)